Replies to post #6766 on Fibrocell Science Inc (FCSC)

[novicetrader]

tried googling but couldn't come up with anything specific.Will look forward to any update you can provide.I think the next catalyst for FCSC is Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB),in the next quarter.

From the recent 5/8 news release:
As specified in the protocol of this Phase 1/2 trial, additional adult patients can begin to be dosed with this recommendation from the DSMB. Six adult patients are targeted for the Phase 1 portion of the trial. Twelve-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in the Phase 1 portion of this trial are expected in the third quarter of 2017.